Global Bevacizumab Biosimilars Market is expected to grow at an 18.4 % CAGR during the forecast period for 2024-2031.
Global Bevacizumab Biosimilars Market is expected to grow at an 18.4 % CAGR during the forecast period for 2024-2031.
The market for bevacizumab biosimilars, a biologic medication used to treat different kinds of cancer, has grown significantly in the last few years. This increase can be ascribed to the high cost of the original medication as well as the rising incidence of cancer throughout the globe. The market is growing as a result of the launch of bevacizumab biosimilars, which have given consumers and healthcare providers a more affordable option.
The market for bevacizumab biosimilars is anticipated to continue growing in the upcoming years due to the growing emphasis on biosimilars and the original medication’s patent expiring. To take advantage of the potential this expanding market presents industry players.
Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/1073
Recent Developments:
- In December 2023, Bio-Thera Solutions received USFDA approval for fifth bevacizumab biosimilar, Avzivi (bevacizumab-tnjn) for the treatment of several types of cancers including metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer and epithelial ovarian cancer.
- In November 2022, the global biosimilars business of Viatris Inc. was successfully bought by Biocon Biologics Ltd., an India-based company and subsidiary of Biocon Ltd., for an undisclosed sum. Biocon Biologics Ltd. is involved in the manufacturing of biopharmaceuticals. The goal of this calculated acquisition is to increase Biocon Biologics’ market share in the biosimilars industry. With notable drugs like Bevacizumab, Viatris Inc. is a US-based pharmaceutical and healthcare company that specializes in medicines for important therapeutic areas, including cancer.
List of Prominent Players in the Global Bevacizumab Biosimilar Market:
- Hetero Drugs Ltd
- Amgen Inc
- Biocon Ltd
- Mylan Inc
- BioXpress Therapeutics SA
- Celltrion Inc
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- Dr. Reddy’s Laboratories Ltd.
- Genor Biopharma
- Harvest Moon Pharmaceuticals
- Innovent Biologics
- Laboratorio Elea
- mAbxience S.A
- Mycenax Biotech
- Outlook Therapeutics
- Reliance Life Sciences
- Samsung Bioepis
- Shanghai Henlius Biotech
- Tanvex Biopharma
- Zhejiang Teruisi Pharmaceutical
- Zydus Cadila
Market Dynamics:
Drivers-
The market for bevacizumab biosimilars is anticipated to grow in the future due to the increasing incidence of cancer cases. The number of new cancer cases in a particular population over a specified time period is referred to as cancer incidence. A significant trend that is becoming more and more popular in the bevacizumab biosimilars market is product innovation. Large industry participants are focusing their efforts on developing cutting-edge items in order to bolster their market share. In addition, the bevacizumab biosimilars market is witnessing substantial growth, driven in part by the increasing availability and adoption of biosimilar monoclonal antibodies, including those targeting bevacizumab.
Challenges:
Bevacizumab is a sophisticated biological medication that is expensive to produce. Because of this, a significant portion of the population cannot afford medicines, particularly in developing and low-income nations. The high price of bevacizumab might prevent it from being widely used, which would impede market expansion.
Regional Trends:
North America was the largest region in the bevacizumab biosimilars market in 2023. Owing to the rising use of bevacizumab in the treatment of different forms of cancer, Europe has the second largest revenue generating region. Owing to rising healthcare spending and prevalence, Asia-Pacific is anticipated to hold the most market share in the upcoming years.
Segmentation of Global Bevacizumab Biosimilar Market –
Global Bevacizumab Biosimilar Market – Product
- Vegzelma
- Alymsys
- Mvasi
- Zirabev
- Aybintio
- Other Clinical Trial Product
Global Bevacizumab Biosimilar Market – Application
- Non-squamous Non-small Cell Lung Cancer
- Recurrent Glioblastoma
- Cervical Cancer
- Colorectal Cell Cancer
- Ovarian Cancer
- Proliferative Diabetic Retinopathy
- Malignant Glioma
- Neurofibromatosis
- Pancreatic Cancer
- Others
Global Bevacizumab Biosimilar Market – Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bevacizumab Biosimilar Market – By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Order the 180 Pages Detailed Report @ https://www.insightaceanalytic.com/buy-report/1073
Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com